Gina Mangin, MPAS, PA-C, discusses how measuring atopic dermatitis treatment success requires evaluating multiple factors, including reduction in itch intensity, improvement in sleep quality, decreased flare frequency, enhanced quality of life, and visible skin healing through standardized assessment tools and patient-reported outcomes.
Jordan Bui and Bernard A. Cohen, MD, review a case of a young patient with vitiligo.
David Rosmarin, MD, shared his insights on the study in a Q&A with Dermatology Times.
Bradley Burnam discusses results from an in-vivo model of atopic dermatitis.
Earlier this summer, Meghan Heberton, MD, emphasized the importance and growth of the subspecialty.
Catch up on exclusive interviews with Christopher Bunick, MD, PhD; Raj Chovatiya, MD, PhD; and Alexander Egeberg, MD, PhD, from quarter 4 dermatologic conferences.
Experts in the field share why they enjoyed the 5th Annual Revolutionizing Atopic Dermatitis Conference and why it is unique.
John Browning, MD, FAAD, FAAP, MBA, discusses the new online platform that allows young patients to share their skin journey with others.
Mickey Bryson describes the impact of atopic dermatitis on his quality of life and family, and the session concludes with final reflections.
Pharmacists play a role in advising patients with hair loss about self-management and proper application of over the counter products.
Explore how BCs are supported through complex drug approvals and ensuring patients have access to prescribed medications.
A panelist discusses how selecting the optimal laser device requires careful consideration of wavelength, pulse duration, and spot size to effectively target specific skin concerns while minimizing potential adverse effects.
It is crucial to better understand, diagnose, and manage this skin condition associated with significant quality-of-life impairment.
Understanding the difference in biology and clinical presentations of cutaneous conditions in different skin types is critical for health care professionals to treat a diverse population.
Given the complexity of the underlying inflammation in patients with AD, an increased understanding of the OX40L pathway can improve our understanding of AD pathogenesis.
Graber spoke with Dermatology Times to share the top clinical pearls and key takeaways from the recent meetings.
Sonya Kenkare, MD, explains her approach to itch and the support system of multiple specialties to help a pediatric patient with atopic dermatitis.
Frequent fliers, including pilots and cabin crew, are exposed to greater levels of UV and cosmic ionizing radiation than the general population, leading to higher incidence of skin cancers.
In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.
Second-line end points of the TRICOTEL trial assessing atezolizumab plus vemurafenib and cobimetinib in melanoma with central nervous system metastases appear consistent with primary efficacy end points.
A variety of topicals and biologics are now available to treat children affected by this challenging condition.
It is important for pediatric and family nurse practitioners caring for patients with dermatological conditions to be comfortable talking about the conditions with children, adolescents, and their parents.
This expert review explores the multifaceted causes of female hair loss—hormonal imbalances, inflammation, nutrient deficiencies, aging, and oxidative stress—and explores non-pharmaceutical interventions.